Clinical Trials in Bakersfield, California
79 recruiting
Showing 1–20 of 79 trials
Recruiting
Phase 3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled235 locationsNCT06662786
Recruiting
Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Hypertriglyceridemia
Arrowhead Pharmaceuticals869 enrolled248 locationsNCT06822790
Recruiting
Objective Assessment of Intraocular Lens Tilt and Decentration
Tilt and Decentration
Johnson & Johnson Surgical Vision, Inc.80 enrolled2 locationsNCT07324200
Recruiting
Phase 3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled241 locationsNCT06750094
Recruiting
Phase 2
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled125 locationsNCT06770582
Recruiting
Phase 2
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
HIV Infections
ViiV Healthcare150 enrolled113 locationsNCT07202546
Recruiting
Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled94 locationsNCT06510374
Recruiting
Phase 3
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
Chronic Inducible UrticariaCold UrticariaSymptomatic Dermographism+1 more
Celldex Therapeutics240 enrolled72 locationsNCT07266402
Recruiting
Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled536 locationsNCT06058377
Recruiting
Phase 2Phase 3
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
NRG Oncology1,912 enrolled1056 locationsNCT05174169
Recruiting
Patient Retrospective Outcomes (PRO)
Chronic Pain
Boston Scientific Corporation15,000 enrolled143 locationsNCT01550575
Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Heart FailureArrhythmiaBradycardia+1 more
Medtronic20,000 enrolled320 locationsNCT00271180
Recruiting
Phase 3
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Chronic Spontaneous Urticaria
Novartis Pharmaceuticals100 enrolled65 locationsNCT05677451
Recruiting
Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
COVID-19 (SARS-CoV-2) infection
Pfizer2,330 enrolled103 locationsNCT06679140
Recruiting
Phase 3
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Diabetic Macular Edema (DME)Diabetic Macular EdemaDME
EyePoint Pharmaceuticals, Inc.240 enrolled46 locationsNCT07449936
Recruiting
Phase 3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche2,000 enrolled484 locationsNCT05878769
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Asthma
Teva Branded Pharmaceutical Products R&D LLC2,700 enrolled393 locationsNCT06052267
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled216 locationsNCT06345729
Recruiting
Phase 1Phase 2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Non Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC32 enrolled13 locationsNCT06637423